We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety (rTMSinCP)

This study is currently recruiting participants.
Verified October 2016 by Mehmet Dokucu, Northwestern University
Sponsor:
ClinicalTrials.gov Identifier:
NCT01701284
First Posted: October 5, 2012
Last Update Posted: October 4, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Neuronetics
Information provided by (Responsible Party):
Mehmet Dokucu, Northwestern University
October 3, 2012
October 5, 2012
October 4, 2016
December 2012
August 2017   (Final data collection date for primary outcome measure)
  • Overall change in depression severity [ Time Frame: 0, 2, 4, and 6 weeks ]
    Overall change in depression severity (as measured by the Hamilton Depression Rating Scale) will be measured for each treatment arm.
  • Relative change in depression severity [ Time Frame: 0, 2, 4, and 6 weeks ]
    Change in depression severity (as measured by the Hamilton Depression Rating Scale) for a treatment arm will be compared relative to change in depression severity in the other treatment arm.
  • Presence and changes in severity of side effects [ Time Frame: 0, 2, 4, and 6 weeks ]
    At weeks 2, 4 and 6, UKU Side Effects Rating Scale scores will be compared to baseline UKU scores to determine changes in presence and severity of side effects. Additionally, UKU scores at weeks 2, 4, and 6 will be used to determine probability that side effects are related to intervention.
Same as current
Complete list of historical versions of study NCT01701284 on ClinicalTrials.gov Archive Site
  • Overall change in anxiety severity [ Time Frame: Weekly (starting with week 0 through week 6) ]
    Overall change in anxiety severity (as measured by the Hamilton Anxiety Rating Scale) will be measured for each treatment arm.
  • Relative change in anxiety severity [ Time Frame: Weekly (starting with week 0 through week 6) ]
    Change in anxiety severity (as measured by the Hamilton Anxiety Rating Scale) for a treatment arm will be compared relative to change in anxiety severity in the other treatment arm.
  • Correlation of anxiety with change in depression severity [ Time Frame: 0 and 6 weeks ]
    Baseline anxiety severity (as measured by the Hamilton Anxiety Rating Scale) will be correlated with change (from baseline to end of week 6) in depression severity (as measured by the Hamilton Depression Rating Scale) for each treatment arm and compared.
  • Correlation of anxiety with harm avoidance personality trait [ Time Frame: Baseline ]
    Baseline anxiety severity (as measured by the Hamilton Anxiety Rating Scale) will be correlated with Harm Avoidance scores from the TCI personality inventory
Same as current
Not Provided
Not Provided
 
Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety
A Randomized Open-Label Pilot Trial To Evaluate The Safety And Efficacy Of Repetitive Transcranial Magnetic Stimulation In Cancer Patients With Depression And Anxiety
Cancer is a leading cause of mortality and morbidity worldwide. In addition, cancer is associated with high rates of depression and anxiety among its sufferers, and cancer patients with depression usually have worse treatment outcomes and long-term survival. Surprisingly, many cancer patients with depression do not receive treatment for their depression, perhaps because treatments for cancer-related depression are usually adapted from those used in non-cancer populations and may not be suitable for cancer patients. Moreover, cancer patients with depression are more likely to have a long latency of anti-depressant drug action, negative drug-drug interactions with cancer chemotherapies and an increased susceptibility for systemic side effects. Repetitive transcranial magnetic stimulation (rTMS) is a new treatment modality for depression that affects the brain directly with no systemic side effects and poses no potential for drug-drug interactions. rTMS therapy was recently cleared by the FDA as an antidepressant treatment for treatment-resistant Major Depressive Disorder, and now is being evaluated for a wide array of additional psychiatric indications. This randomized, open label, two-arm, pilot study will investigate the safety, tolerability, feasibility and the efficacy of two forms of rTMS (i.e., left (fast) and right (slow) sided rTMS) in cancer-related depression. The study hypotheses are that rTMS will significantly reduce symptoms of depression and that right-sided slow rTMS will be more effective than left-sided fast rTMS for the treatment of severe anxiety.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Cancer in Remission (Any Type or Stage)
  • Depression
  • Anxiety
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
Other Name: Neurostar TMS Therapy(R) System
  • Experimental: Right-Sided Low-Frequency rTMS
    Participants will have rTMS administered at 1Hz to the right dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
    Intervention: Device: Repetitive Transcranial Magnetic Stimulation (rTMS)
  • Experimental: Left-Sided High-Frequency rTMS
    Participants will have rTMS administered at 10Hz to the left dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
    Intervention: Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
August 2018
August 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female
  • Age 22-70
  • Had a previous diagnosis of cancer (any type or stage) confirmed by official medical records
  • Has a DSM IV diagnosis of Major Depressive Disorder
  • Has a HAM-D 24-item score of more than 20
  • Failed to receive satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current depressive episode
  • All participants must have given signed, informed consent prior to registration in study

Exclusion Criteria:

  • Participant had breast cancer with brain metastases
  • There is evidence of the disease at the time of entry into the trial
  • Presence or recent history of other concurrent cancers, with the following exceptions:

    • Participants with completely treated basal or squamous skin cancers can be included in the study if their physicians deem that they are medically stable
    • Participants with completely treated in situ carcinoma of the breast or cervix may be included in the study if they have not had chemotherapy within the past month and their physicians deem that they are medically stable
    • Participants with pre-cancerous lesions in the colon can be included in the study if they have not had chemotherapy within the past month and their physicians deem that they are medically stable
  • Participant had recent surgery (within two weeks)
  • Participant is undergoing chemotherapy
  • Participant is pregnant or nursing
  • Participant has any metallic object in or around their head
  • Participant has a pacemaker
  • Has unstable suicidal ideation as determined by the patient's treating psychiatrist
  • Substance use disorder within the prior six months
  • Significant history of head injury/trauma as defined by loss of consciousness for more than 1 hour
  • Recurring seizures resulting from the head injury
  • Clear cognitive sequelae from the head injury and cognitive rehabilitation following the injury
  • Any disorder that would predispose the participant to seizures
  • Use of concomitant medications that substantially increase seizure risk. Such drugs could include neuroleptics (ex. haloperidol, droperidol), clozapine, tricyclic antidepressants (ex. amoxapine, clomipramine), bupropion (particularly the immediate release - IR - formulation) donepezil, psychostimulants (ex. methylphenidate), theophylline and/or other drugs that reduce the seizure threshold. For individuals on any of these medicines, a study clinician will evaluate the drugs and doses to determine the risks and benefits. These will then be discussed with the individual's Primary Care Physician to determine if the individual should be excluded from the study.
Sexes Eligible for Study: Female
22 Years to 70 Years   (Adult, Senior)
No
Contact: Marko Mihailovic (312) 503-9096 marko.mihailovic@northwestern.edu
United States
 
 
NCT01701284
NU 12CC12
NCI-2012-01691 ( Registry Identifier: NCI Clinical Trials Reporting Program (CTRP) )
Yes
Not Provided
Plan to Share IPD: No
Mehmet Dokucu, Northwestern University
Northwestern University
Neuronetics
Principal Investigator: Mehmet Dokucu, MD, PhD Northwestern University
Northwestern University
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP